logo
  

Fiserv Q4 Profit Matches Estimates - Quick Facts

Fiserv, Inc. (FISV) reported fourth-quarter income from continuing operations of $181 million or $0.73 per share, compared to $220 million or $0.84 per share, prior year. The company noted that the prior year fourth quarter GAAP earnings per share from continuing operations included a $0.21 per share gain on the partial divestiture of a subsidiary business at StoneRiver Group, L.P., a joint venture in which the company owns a 49% interest. Adjusted earnings per share from continuing operations was $0.89, for the quarter.

On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.89 for the quarter. Analysts' estimates typically exclude special items.

Revenue increased to $1.32 billion from $1.26 billion last year. Analysts expected revenue of $1.32 million for the quarter. Adjusted revenue was $1.23 billion in the fourth quarter.

For 2015, Fiserv expects adjusted internal revenue to grow in a range of 5 to 6 percent. The company also expects adjusted earnings per share in a range of $3.73 to $3.83. Analysts expect the company to report 2015 earnings per share of $3.78.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT